- Home
- CLLS vs AMRN Comparison
CLLS vs AMRN Comparison
Compare CLLS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- AMRN
- Stock Information
- Founded
- CLLS 1999
- AMRN 1989
- Country
- CLLS France
- AMRN Ireland
- Employees
- CLLS 216
- AMRN N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- AMRN Health Care
- Exchange
- CLLS Nasdaq
- AMRN Nasdaq
- Market Cap
- CLLS 148.1M
- AMRN 189.2M
- IPO Year
- CLLS 2007
- AMRN 1993
- Fundamental
- Price
- CLLS $1.48
- AMRN $0.56
- Analyst Decision
- CLLS Buy
- AMRN Buy
- Analyst Count
- CLLS 3
- AMRN 1
- Target Price
- CLLS $7.00
- AMRN N/A
- AVG Volume (30 Days)
- CLLS 235.1K
- AMRN 1.7M
- Earning Date
- CLLS 11-04-2024
- AMRN 02-27-2025
- Dividend Yield
- CLLS N/A
- AMRN N/A
- EPS Growth
- CLLS N/A
- AMRN N/A
- EPS
- CLLS N/A
- AMRN N/A
- Revenue
- CLLS $36,042,000.00
- AMRN $241,021,000.00
- Revenue This Year
- CLLS $387.77
- AMRN N/A
- Revenue Next Year
- CLLS $11.14
- AMRN N/A
- P/E Ratio
- CLLS N/A
- AMRN N/A
- Revenue Growth
- CLLS 46.96
- AMRN N/A
- 52 Week Low
- CLLS $1.41
- AMRN $0.43
- 52 Week High
- CLLS $3.38
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- CLLS 38.66
- AMRN 60.59
- Support Level
- CLLS $1.65
- AMRN $0.43
- Resistance Level
- CLLS $2.23
- AMRN $0.49
- Average True Range (ATR)
- CLLS 0.18
- AMRN 0.03
- MACD
- CLLS -0.03
- AMRN 0.01
- Stochastic Oscillator
- CLLS 8.54
- AMRN 91.43
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.